MANNKIND CORPORATION

Sector revisions MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
5.780 ^USD	+4.90%		0.00%	+1.94%

01-26	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
01-26	MannKind Corporation Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching from Multiple Daily Injections or Insulin Pump Mealtime Therapy	CI

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	MANNKIND CORPORATION							9
	ARGENX SE							15
	WUXI APPTEC CO., LTD.							18
	INSMED INCORPORATED							20
	BIONTECH SE							19
	WUXI BIOLOGICS (CAYMAN) INC.							24
	GENMAB A/S							13
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							17
	AKESO, INC.							21
	EXELIXIS, INC.							18
	SUMMIT THERAPEUTICS INC.							13
	MADRIGAL PHARMACEUTICALS, INC.							15
	SAMSUNG EPIS HOLDINGS CO., LTD.				-	-	-	1
	ARROWHEAD PHARMACEUTICALS, INC.							12
	PHARMAESSENTIA CORPORATION							6
	VAXCYTE, INC.							9
	NUVALENT, INC.							17
	Average							15
	Weighted average by Cap.							16

Bio Therapeutic Drugs

The best tools reserved for subscribers to boost the performance of your investments!